A clinical study of the effect of calcium sodium phosphosilicate on dentin hypersensitivity-Proof of principle

Abstract

Objective: NovaMin®is technically described as amorphous sodium calcium phosphosilicate, and has been shown in laboratory studies to rapidly occlude dentin tubules through the deposition of particles that react to form a protective layer, similar to bone mineral, on the dentin surface. NovaMin was originally developed as a bone regenerative material and is highly biocompatible. The objective of this pilot study was to compare the safety and effectiveness of two prototype formulations containing 2.5% and 7.5% w/w NovaMin to a placebo dentifrice for the treatment of dentin hypersensitivity. Methods: This was a randomized, double-blind, placebo-controlled pilot study. Sixty-six subjects with a confirmed diagnosis of dentin hypersensitivity were randomized to one of three treatments: 2.5% NovaMin, 7.5% NovaMin, or placebo. Two standard test stimuli, tactile and thermal air, were applied to sensitive cervical dentin surfaces. Subjects recorded the intensity of sensitivity in response to each stimulus on a visual analog scale at baseline, and after two, four, and eight weeks of twice-daily product use. Oral soft tissues were examined and spontaneous reports of adverse experiences were also monitored. Results: Comparison of the mean change from baseline among the three treatment groups indicated a meaningful reduction in sensitivity scores in the 7.5% group that was significant compared to reductions observed in the placebo control group at all time points. Conclusion: The results of this study are supportive of the incorporation of NovaMin into products intended for the reduction of dentin hypersensitivity.